We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF) (GP)

This study is currently recruiting participants.
Verified July 2017 by Kevin F. Gibson, University of Pittsburgh
Sponsor:
ClinicalTrials.gov Identifier:
NCT00258570
First Posted: November 24, 2005
Last Update Posted: July 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Kevin F. Gibson, University of Pittsburgh
  Purpose

The purposes of this study are:

  • to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis;
  • to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs.

Condition
Pulmonary Fibrosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Other
Official Title: Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis

Resource links provided by NLM:


Further study details as provided by Kevin F. Gibson, University of Pittsburgh:

Biospecimen Retention:   Samples With DNA
Blood samples retained for multitude of testing. Consent allows for unrestricted use of samples.

Estimated Enrollment: 2000
Study Start Date: January 2003
Estimated Study Completion Date: July 2020
Estimated Primary Completion Date: July 2020 (Final data collection date for primary outcome measure)
Detailed Description:
Idiopathic pulmonary fibrosis is one of a collection of severe lung diseases that lead to abnormal inflammation and scarring of the lungs. The accumulation of scar tissue in the lung destroys normal lung tissue and results in the symptoms associated with this disease. The cause of the disease is currently unknown. In this study, we are attempting to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis. We are also attempting to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs. The purpose of this research is to identify genes that control the processes of lung inflammation, lung scarring, and lung repair. As more information becomes available, we will also conduct studies of additional genes that are found to be involved in this disease process.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient population includes patients who have been diagnosed with a fibrotic interstitial lung disease who have been seen by a Simmons Center Physician.
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Diagnosis of pulmonary fibrosis confirmed by physical examination, pulmonary function testing, chest X-ray, and computed tomography (CT) scans.
  • Adult patients who are seeking treatment at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.

Exclusion Criteria:

  • Under 18 years of age
  • Non-fibrotic ILD
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00258570


Contacts
Contact: Melinda J Klesen, BA 412-802-6860 ext 26860 klesenmj@upmc.edu
Contact: Morgan Kirkpatrick, BS 412-692-2151 ext 22151 kirkpatrickml@upmc.edu

Locations
United States, Pennsylvania
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Melinda J Klesen, BA    412-802-6860 ext 26860    klesenmj@upmc.edu   
Contact: Morgan L Kirkpatrick, BS    412-692-2151 ext 22151    kirkpatrickml@upmc.edu   
Sub-Investigator: Yingze Zhang, PhD         
Sub-Investigator: Sam Yousem, MD         
Sub-Investigator: Rajiv Dhir, MD         
Sub-Investigator: Prabir Ray, PhD         
Sub-Investigator: Kathleen O. Lindell, R.N., M.S.N         
Sub-Investigator: Luis A Ortiz, M.D.         
Sub-Investigator: Daniel J. Kass, M.D.         
Sub-Investigator: Kristen Veraldi, M.D.         
Principal Investigator: Kevin F. Gibson, M.D.         
Sub-Investigator: Michelle F. MacPherson, BS, MAT         
Sub-Investigator: Michelle Meyers, BSN, RN         
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Kevin F Gibson, MD University of Pittsburgh, Simmons Center for ILD
  More Information

Additional Information:
Responsible Party: Kevin F. Gibson, Professor of Medicine, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00258570     History of Changes
Other Study ID Numbers: 020123
First Submitted: November 23, 2005
First Posted: November 24, 2005
Last Update Posted: July 25, 2017
Last Verified: July 2017

Keywords provided by Kevin F. Gibson, University of Pittsburgh:
"Lung[A04.400]"

Additional relevant MeSH terms:
Fibrosis
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial